Description:

E1105 Quality of Life Assessment Form First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=17363D95-6129-3B27-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=17363D95-6129-3B27-E044-0003BA3F9857

Keywords:

Quality of Life

Breast Neoplasms

Uploaded on:

January 9, 2015

DOI:

To request one please log in.

License :

Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Quality of Life Assessment Form (E1105)

INSTRUCTIONS: After patient is off treatment, complete this form for each required follow-up report period (see forms submission schedule).

StudyEvent: E1105 Quality of Life Assessment Form
1. INSTRUCTIONS: After patient is off treatment, complete this form for each required follow-up report period (see forms submission schedule).

Administrative documentation

ECOG Protocol Number

ECOG Patient ID

DCI Name

Registration Step

Patient Initials (Last, First)

ECOG Protocol Number

Participating Group Protocol Number

Institution/Affiliate

ECOG Patient ID

Participating Group Patient ID

Please mark an 'X' if data have been amended (Please circle amended items in red)

Date data amended (M D Y)

Back to the top of the page

Similar models

Show recommended models

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.